Clinical Trial of High Dose CoQ10 in ALS

Coenzyme Q10 (CoQ10) is a mitochondrial cofactor and powerful antioxidant. It prolongs survival in the mouse model of ALS. Also, it has shown promise in a clinical trial of Parkinson’s disease, another neurodegenerative disease. CoQ10 is a natural supplement. In this study, we will evaluate the safety and effectiveness of a new high dose CoQ10 preparation that is well absorbed when taken by mouth.

Many ALS centers throughout the US will participate in this study. During the study’s first phase, patients will be randomized to high dose, very high dose, or placebo. During the second stage patients will be randomized to receive either the preferred dose (found in stage 1) or placebo. Enrollment will begin in early October 2004. The study is designed to make participation easy on patients. Most study visits are 2 months apart, and there is no tiring muscle testing involved. Each patient will participate in the trial for 9 months.

If you would like more information about this trial or the participating trial site nearest you please contact:

Alexandra I. Barsdorf, MA
Clinical Study Coordinator
Eleanor and Lou Gehrig MDA/ALS Research Center
The Neurological Institute
Columbia University
710 West 168th Street
New York, NY 10031
(212) 342-3026 or aib2104@columbia.edu